2023 Tandem Meetings

The 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR highlight the most innovative research in the field of hematopoietic cell transplantation and cellular therapy. This year, they are held on February 15-19 in Orlando, Florida. During the Tandem Meetings, leading experts from around the world will present the latest developments during plenaries, concurrent sessions, oral abstracts, posters, tracks, meet-the-professor sessions, and more.

THRIVE Study Recruiting Patients With Chronic Graft-Versus-Host Disease
The problem of chronic graft-versus-host disease (cGVHD) for allogeneic hematopoietic cell transplant (alloHCT) patients is incredibly pervasive. However, there is surprisingly little centralization of outcomes and disease-course data. One currently enrolling study seeks to change that. The THRIVE study is a prospective, longitudinal, observational study of United States alloHCT recipients that primarily seeks to “assess the clinical course and burden of cGVHD, including cGVHD diagnosis and severity recorded in electronic case report forms (eCRFs) and [patient]-reported outcome measures (PROMs).” ...
Advertisement
Dustin SamplesConferences | February 22, 2023
Steroid-dependent acute GVHD was most likely to lead to chronic GVHD. What other relationships were observed?
Read More
Dustin SamplesConferences | February 22, 2023
Increases in α-ketoglutarate, glutamic acid, and kynurenine were observed in patients with chronic GVHD.
Dustin SamplesConferences | February 22, 2023
Chronic GVHD commonly affects the orofacial cavity, but what are the characteristics and management strategies?
Dustin SamplesConferences | February 21, 2023
Low-dose interleukin-2 was safe and well-tolerated as a steroid-sparing agent for pediatric cGVHD.
Dustin SamplesConferences | February 21, 2023
Does palifermin affect the cumulative incidence of acute or chronic GVHD when added to standard TMS prophylaxis?
Dustin SamplesConferences | February 21, 2023
Do cytopenias affect the outcome of treatment with ruxolitinib versus best available therapy for steroid-refractory aGVHD?
Dustin SamplesConferences | February 21, 2023
Continuous intravenous tacrolimus administration can be logistically challenging. Can intermittent dosing work as well?
Dustin SamplesConferences | February 18, 2023
Is it better to find a matched-unrelated donor or wait for a haploidentical donor for allogeneic HCT?
Dustin SamplesConferences | February 18, 2023
How does the recipient's immune profile affect outcomes of unrelated-donor allogeneic HCT?
Dustin SamplesConferences | February 18, 2023
Do outcomes differ when using cryopreserved versus fresh grafts for haploidentical allogeneic hematopoietic cell transplant?
Dustin SamplesConferences | February 18, 2023
When a prospective donor does not have the mental capacity to provide informed consent, what steps can be taken?
Dustin SamplesGVHD | February 16, 2023
Vascular access events caused most patients to discontinue treatment. Does catheter type affect event frequency?
Dustin SamplesGVHD | February 16, 2023
Can extracorporeal photopheresis treat acute graft-versus-host disease when the disease has become steroid dependent?
Dustin SamplesConferences | February 16, 2023
Low absolute lymphocyte count was associated with increased risk of acute GVHD and non-relapse mortality.
Dustin SamplesConferences | February 16, 2023
The highest overall response rate occurred on day 29 for those who received 1.6 mg/kg.
Dustin SamplesConferences | February 15, 2023
These peptides are the target for CD8+ T cells, but does the total or type matter more?
Dustin SamplesGVHD | February 15, 2023
The accepted belief is that late-onset acute GVHD is less severe, but one study demonstrated the opposite.
Dustin SamplesConferences | February 15, 2023
The prophylactic trio outperformed historical records of prophylaxis with cyclosporine and methotrexate.
Dustin SamplesConferences | February 15, 2023
A promising new therapy for haploidentical hematopoietic cell transplant showed no need for the toxic chemotherapeutic.
Advertisement
Advertisement
Advertisement